Your AI-Trained Oncology Knowledge Connection!
Scientists have found a way to detect earlier if Merkel cell carcinoma (MCC) is recurring in patients. They have published a paper in the journal Cancer demonstrating how an immune system marker may be able to outperform and supplement imaging studies for recurrence of MCC.
Reducing the use of indoor tanning by enforcing an age restriction could potentially reduce melanoma incidence, mortality, and the costs associated with treating the disease, according to results of an economic analysis.
Researchers have identified characteristics associated with improved outcomes when treating BRAF-mutated advanced melanoma with the combination of dabrafenib and trametinib.
An individual’s clinical risk factors could help guide skin cancer screening and identify those at high risk for melanoma who could benefit from increased surveillance.
Researchers from Moffitt Cancer Center’s Integrated Mathematical Oncology (IMO) Department are overcoming some of the limitations of common preclinical experiments and clinical trials by studying cancer through mathematical modeling.
Myocarditis is a rare and sometimes lethal complication of combination immune checkpoint blockade for metastatic melanoma.
Immune checkpoint inhibitor-related neurotoxicities are more frequent in clinical practice than clinical trials.
Results of a meta-analysis revealed that BRAF/MEK and PD-1 inhibition significantly improved survival in BRAF-mutated melanoma compared with other treatments.
In this interview we discuss the idea of using schools to increase knowledge about skin cancer and attitudes toward sun exposure.
A 54-year-old woman is found to have a skin lesion in the right arm. What is your diagnosis?
A novel immunotherapy antibody was safe and showed modest antitumor activity in a phase I clinical trial in advanced melanoma.
Waiting as long as 3 months from a melanoma diagnosis to sentinel lymph node biopsy had no effect on 5-year survival or sentinel node positivity rate, according to the results of a study.
Ironically, the patients who can benefit the most from CLND in terms of regional nodal basin disease control are the patients who are least likely to experience a survival benefit.
CLND as standard of care for patients with SLN-positive metastatic melanoma is supported by a wealth of compelling prospective data.
Objective tumor responses to pembrolizumab (Keytruda) and nivolumab (Opdivo) are associated with longer times between melanoma diagnosis and treatment.
An experimental checkpoint inhibitor called avelumab may produce quick and durable responses in some patients with metastatic Merkel cell carcinoma.
A large percentage of patients with metastatic melanoma in Europe may not have access to innovative medicines used to treat the disease, according to the results of a survey.
Melanoma patients diagnosed prior to age 18 had a higher survival vs adult patients, despite having similar tumor depth and more frequent nodal metastases.
Researchers at Moffitt Cancer Center in Tampa, Fla., demonstrated how novel immune and targeted therapies with radiation therapy may improve the outcomes of patients with melanoma who have brain metastases.
Combining the BRAF inhibitor encorafenib with the MEK inhibitor binimetinib may significantly improve progression-free survival in BRAF mutant melanoma, according to a new phase III trial.
Lack of knowledge and a belief that dark skin protects against skin cancer are among the barriers preventing minority, uninsured, and immigrant populations from adopting methods for skin cancer prevention.
The use of sunscreen with an SPF of 15 or greater was associated with about a 30% reduction in the risk for melanoma among a group of Norwegian women.
Researchers from the University of Virginia Cancer Center are now reporting that the experimental agent pevonedistat may be able to combat melanoma in whole new way.
Researchers at the Massachusetts Institute of Technology have engineered a remote control switch that uses ultraviolet (UV) light to activate CRISPR-Cas9 gene editing.
Oral vitamin D intake was associated with an increased risk for basal cell carcinoma, but not melanoma, according to two large cohort studies.
